Shindoh Junichi, Chun Yun Shin, Loyer Evelyne M, Vauthey Jean-Nicolas
The Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1484, Houston, TX 77030.
Curr Colorectal Cancer Rep. 2013 Jun 1;9(2):198-202. doi: 10.1007/s11888-013-0164-7.
Since the introduction of biologic agents, increasing data have suggested that conventional size-based RECIST criteria are not accurate in the assessment of response to therapy and non-size-based changes in tumor morphology can be a surrogate marker for assessment of chemotherapeutic effect. The morphologic response criteria are recently introduced, non-size-based criteria for patients undergoing chemotherapy for colorectal liver metastases (CLM). These novel criteria predict pathologic response and long-term survival of patients treated with preoperative chemotherapy, with or without bevacizumab, independent of their RECIST response. They have been validated in patients with resectable and unresectable CLM. These criteria are difficult to apply in small metastases and can be used as an adjunct to RECIST in the assessment of response to preoperative chemotherapy.
自生物制剂引入以来，越来越多的数据表明，传统的基于大小的RECIST标准在评估治疗反应方面并不准确，而肿瘤形态的非大小改变可作为评估化疗效果的替代指标。形态学反应标准是最近引入的，用于接受结直肠癌肝转移（CLM）化疗患者的非大小标准。这些新标准可预测接受术前化疗（无论是否使用贝伐单抗）患者的病理反应和长期生存情况，与他们的RECIST反应无关。它们已在可切除和不可切除的CLM患者中得到验证。这些标准在小转移灶中难以应用，可作为RECIST的辅助手段用于评估术前化疗的反应。
